Reuters logo
3 years ago
BRIEF-Biotec Pharmacon ASA Q2 EBITDA NOK -2.3 mln, sees higher revenues in 2H vs 2H 2013
August 13, 2014 / 5:03 AM / 3 years ago

BRIEF-Biotec Pharmacon ASA Q2 EBITDA NOK -2.3 mln, sees higher revenues in 2H vs 2H 2013

Aug 13 (Reuters) - Biotec Pharmacon ASA : * Q2 revenues NOK 5.4 mln (2.7 mln) * Q2 EBITDA NOK -2.3 million versus loss NOK 4.7 million * Q2 pretax profit NOK -2.5 mln(-4.9 mln) * Expects overall revenue growth in the second half of the year compared to

last year (sales revenues in 2H 2013 was 7.2 mln) * Expect that market evaluation for Woulgan Biogel, which will determine commercial strategy, will be finalized during the second half of the year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below